New treatment options for patients with brain metastases from ovarian cancer
Brain metastases from ovarian cancer are quite rare: they affect no more than 0.5–3.0 % of patients according to the literature. However, the incidence of brain metastasis is increasing, which is attributed to longer survival of ovarian cancer patients and more accurate diagnosis. It is not possible...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2021-10-01
|
| Series: | Опухоли женской репродуктивной системы |
| Subjects: | |
| Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/870 |
| _version_ | 1826557228413353984 |
|---|---|
| author | A. G. Kedrova S. E. Krasilnikov A. G. Vinokurov A. I. Berishvili T. A. Greyan O. P. Krashenkov E. S. Polovnikov |
| author_facet | A. G. Kedrova S. E. Krasilnikov A. G. Vinokurov A. I. Berishvili T. A. Greyan O. P. Krashenkov E. S. Polovnikov |
| author_sort | A. G. Kedrova |
| collection | DOAJ |
| description | Brain metastases from ovarian cancer are quite rare: they affect no more than 0.5–3.0 % of patients according to the literature. However, the incidence of brain metastasis is increasing, which is attributed to longer survival of ovarian cancer patients and more accurate diagnosis. It is not possible to predict metastasis to the central nervous system, because reliable prognostic biomarkers have not been identified so far, although there have been some achievements in the treatment of such patients. Novel pathological and molecular tumor markers allow doctors to plan individual treatment for each patient and ensure good outcome. Many authors recommend combination treatment that includes surgical resection of the cerebral lesion followed by local radiotherapy alone or in combination with pharmacotherapy. The majority of these patients had high-grade serous ovarian carcinoma (HGSOC) and initially responded to chemotherapy with platinum and taxanes, while brain metastases were detected 2 to 4 years after treatment initiation. Mutations in the BRCA1 and BRCA2 genes, as well as expression of androgen receptors in the primary tumor, may be the risk factors for metastases to the central nervous system and, therefore, should determine further treatment strategy. In this article, we analyzed 3 cases of ovarian cancer with brain metastases. |
| first_indexed | 2024-04-10T01:55:36Z |
| format | Article |
| id | doaj.art-a659c48f564f4ee4857215c5bcaa460a |
| institution | Directory Open Access Journal |
| issn | 1994-4098 1999-8627 |
| language | Russian |
| last_indexed | 2025-03-14T08:25:16Z |
| publishDate | 2021-10-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Опухоли женской репродуктивной системы |
| spelling | doaj.art-a659c48f564f4ee4857215c5bcaa460a2025-03-02T13:05:36ZrusABV-pressОпухоли женской репродуктивной системы1994-40981999-86272021-10-0117310611310.17650/1994-4098-2021-17-3-106-113704New treatment options for patients with brain metastases from ovarian cancerA. G. Kedrova0S. E. Krasilnikov1A. G. Vinokurov2A. I. Berishvili3T. A. Greyan4O. P. Krashenkov5E. S. Polovnikov6Department of Oncology, Federal Research and Clinical Center for Specialized Medical Care and Medical Technologies, Federal Biomedical Agency of the Russian Federation;Department of Obstetrics and Gynecology, Academy of Postgraduate Education, Federal Research and Clinical Center, Federal Biomedical AgencyInstitute of Oncology and Neurosurgery, E.N. Meshalkin. National Medical Research Center, Ministry of Health of RussiaDepartment of Neurosurgery, Federal Research and Clinical Center, Federal Biomedical Agency of the Russian FederationDepartment of Obstetrics and Gynecology, Academy of Postgraduate Education, Federal Research and Clinical Center, Federal Biomedical AgencyDepartment of Oncology, Federal Research and Clinical Center for Specialized Medical Care and Medical Technologies, Federal Biomedical Agency of the Russian FederationDepartment of Anticancer Drug Therapy, Central Clinical Hospital with a Polyclinic of the Administrative Department of the President of the Russian FederationInstitute of Oncology and Neurosurgery, E.N. Meshalkin. National Medical Research Center, Ministry of Health of RussiaBrain metastases from ovarian cancer are quite rare: they affect no more than 0.5–3.0 % of patients according to the literature. However, the incidence of brain metastasis is increasing, which is attributed to longer survival of ovarian cancer patients and more accurate diagnosis. It is not possible to predict metastasis to the central nervous system, because reliable prognostic biomarkers have not been identified so far, although there have been some achievements in the treatment of such patients. Novel pathological and molecular tumor markers allow doctors to plan individual treatment for each patient and ensure good outcome. Many authors recommend combination treatment that includes surgical resection of the cerebral lesion followed by local radiotherapy alone or in combination with pharmacotherapy. The majority of these patients had high-grade serous ovarian carcinoma (HGSOC) and initially responded to chemotherapy with platinum and taxanes, while brain metastases were detected 2 to 4 years after treatment initiation. Mutations in the BRCA1 and BRCA2 genes, as well as expression of androgen receptors in the primary tumor, may be the risk factors for metastases to the central nervous system and, therefore, should determine further treatment strategy. In this article, we analyzed 3 cases of ovarian cancer with brain metastases.https://ojrs.abvpress.ru/ojrs/article/view/870brain metastasesovarian cancerbrcatreatmentmanagementpathologydiagnosisradiation therapysurgery |
| spellingShingle | A. G. Kedrova S. E. Krasilnikov A. G. Vinokurov A. I. Berishvili T. A. Greyan O. P. Krashenkov E. S. Polovnikov New treatment options for patients with brain metastases from ovarian cancer Опухоли женской репродуктивной системы brain metastases ovarian cancer brca treatment management pathology diagnosis radiation therapy surgery |
| title | New treatment options for patients with brain metastases from ovarian cancer |
| title_full | New treatment options for patients with brain metastases from ovarian cancer |
| title_fullStr | New treatment options for patients with brain metastases from ovarian cancer |
| title_full_unstemmed | New treatment options for patients with brain metastases from ovarian cancer |
| title_short | New treatment options for patients with brain metastases from ovarian cancer |
| title_sort | new treatment options for patients with brain metastases from ovarian cancer |
| topic | brain metastases ovarian cancer brca treatment management pathology diagnosis radiation therapy surgery |
| url | https://ojrs.abvpress.ru/ojrs/article/view/870 |
| work_keys_str_mv | AT agkedrova newtreatmentoptionsforpatientswithbrainmetastasesfromovariancancer AT sekrasilnikov newtreatmentoptionsforpatientswithbrainmetastasesfromovariancancer AT agvinokurov newtreatmentoptionsforpatientswithbrainmetastasesfromovariancancer AT aiberishvili newtreatmentoptionsforpatientswithbrainmetastasesfromovariancancer AT tagreyan newtreatmentoptionsforpatientswithbrainmetastasesfromovariancancer AT opkrashenkov newtreatmentoptionsforpatientswithbrainmetastasesfromovariancancer AT espolovnikov newtreatmentoptionsforpatientswithbrainmetastasesfromovariancancer |